                                SEQUENCE LISTING

<110> Knee, Deborah
      Herman, Ann
      Wang, Fei
      DiDonato, Michael

<120> Interleukin-2 Antibodies and Antibody
  Complexes

<130> PAT054025-WO-PCT

<140> Not yet assigned 
<141> Not yet assigned  

<160> 104

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRH1 of MAB1, MAB2, MAB3,
      MAB4, MAB5, MAB6, MAB7 and MAB8 according to
      Chothia, heavy chain V region CDR1

<400> 1
Gly Tyr Thr Phe Thr Asp Ser
 1               5          


<210> 2
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRH2 of MAB1 according to
      Chothia, heavy chain V region CDR2

<400> 2
Asn Pro Asp Asn Gly Ile
 1               5      


<210> 3
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRH3 of MAB1, MAB2, MAB3,
      MAB4, MAB5, MAB6, and MAB7 according to Chothia
      and Kabat, heavy chain V region CDR3

<400> 3
Glu Asp Tyr Asn Ser Asp Asp
 1               5          


<210> 4
<211> 12
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRL1 of MAB1 and MAB2
      according to Chothia, light chain V region CDR1

<400> 4
Ser Gln Ser Leu Phe Asp Ser Asp Gly Lys Thr Tyr
 1               5                  10          


<210> 5
<211> 3
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRL2 of MAB1, MAB2, MAB3,
      MAB4, MAB5, MAB6, MAB7 and MAB8 according to
      Chothia, lightchain V region CDR2

<400> 5
Leu Val Ser
 1          


<210> 6
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRL3 of MAB1, MAB2, MAB3,
      MAB4, MAB5, MAB6, MAB7 and MAB8 according to
      Chothia, light chain V region CDR3

<400> 6
Gly Thr His Phe Pro Phe
 1               5      


<210> 7
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRH1 of MAB1, MAB2, MAB3,
      MAB4, MAB5, MAB6, MAB7 and MAB8  according to
      Kabat, heavy chain V region CDR1

<400> 7
Asp Ser Tyr Met Asn
 1               5  


<210> 8
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRH2 of MAB1 according to
      Kabat, heavy chain V region CDR2

<400> 8
Asp Ile Asn Pro Asp Asn Gly Ile Thr Ser Tyr Asn Gln Lys Phe Arg
 1               5                  10                  15      
Gly
    

<210> 9
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRL1 of MAB1 and MAB2
      according to Kabat, light chain V region CDR1

<400> 9
Lys Ser Ser Gln Ser Leu Phe Asp Ser Asp Gly Lys Thr Tyr Leu Asn
 1               5                  10                  15      


<210> 10
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRL2 of MAB1, MAB2, MAB3,
      MAB4, MAB5, MAB6, MAB7 and MAB8 according to
      Kabat, light chain V region CDR2

<400> 10
Leu Val Ser Lys Leu Asp Ser
 1               5          


<210> 11
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRL3 of MAB1, MAB2, MAB3,
      MAB4, MAB5, MAB6, MAB7 and MAB8  according to
      Kabat, light chain V region CDR3

<400> 11
Trp Gln Gly Thr His Phe Pro Phe Thr
 1               5                  


<210> 12
<211> 116
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain V region of MAB1

<400> 12
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 1               5                  10                  15      
Ser Val Arg Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser
            20                  25                  30          
Tyr Met Asn Trp Val Lys Gln Ser His Gly Lys Arg Leu Glu Trp Ile
        35                  40                  45              
Gly Asp Ile Asn Pro Asp Asn Gly Ile Thr Ser Tyr Asn Gln Lys Phe
    50                  55                  60                  
Arg Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Asp Tyr Asn Ser Asp Asp Trp Gly Gln Gly Thr Thr Leu
            100                 105                 110         
Thr Val Ser Ser
        115     


<210> 13
<211> 112
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody light chain V region of MAB1

<400> 13
Asp Val Val Leu Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly
 1               5                  10                  15      
Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Phe Asp Ser
            20                  25                  30          
Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser
        35                  40                  45              
Pro Lys Arg Leu Val Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro
    50                  55                  60                  
Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Tyr Phe Thr Leu Lys Ile
65                  70                  75                  80  
Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys Trp Gln Gly
                85                  90                  95      
Thr His Phe Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
            100                 105                 110         


<210> 14
<211> 348
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain V region of MAB1

<400> 14
gaggtccagc tgcaacaatc tggacctgaa ctggtgaagc ctggggcttc agtgaggata 60
tcctgtaagg cttctggata cacgttcact gactcctaca tgaactgggt gaaacagagc 120
catggaaaga gacttgagtg gattggagat attaatcctg acaatggtat cactagctac 180
aaccagaagt tcaggggcag ggccacattg actgtggaca agtcctccag cacagcctac 240
atggagctcc gcagcctgac atctgaggac tctgcagtct attactgtgc aagagaggat 300
tataattccg acgactgggg ccaaggcacc actctcacag tctcctca              348

<210> 15
<211> 336
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody light chain V region of MAB1

<400> 15
gatgttgtgc tgacccagac tccactcact ttgtcggtta ccattggaca accagcctcc 60
atctcctgca agtcaagtca gagcctcttc gatagtgatg gaaagacata tttgaattgg 120
ttgttacaga ggccaggcca gtctccaaag cgcctagtct atctggtgtc taaactggac 180
tctggagtcc ctgacaggtt cactggcagt ggatcaggga catatttcac actgaaaatc 240
agcagagtgg aggctgagga tttgggaatt tattattgct ggcaaggtac acattttcca 300
ttcacgttcg gctcggggac aaagttggaa attaaa                           336

<210> 16
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRH2 of MAB2 according to
      Chothia, heavy chain V region CDR2

<400> 16
Asn Pro Asn Asn Gly Gly
 1               5      


<210> 17
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRH3 of MAB2 according to
      Chothia and Kabat, heavy chain V region CDR3

<400> 17
Glu Asn Trp Glu Gly Asp Asn
 1               5          


<210> 18
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRH2 of MAB2 according to
      Kabat, heavy chain V region CDR2

<400> 18
Asp Ile Asn Pro Asn Asn Gly Gly Thr Ser Tyr Asn Arg Lys Phe Lys
 1               5                  10                  15      
Gly
    

<210> 19
<211> 116
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain V region of MAB2

<400> 19
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Thr
 1               5                  10                  15      
Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser
            20                  25                  30          
Tyr Met Asn Trp Met Lys Glu Ser His Gly Lys Ser Leu Glu Trp Ile
        35                  40                  45              
Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ser Tyr Asn Arg Lys Phe
    50                  55                  60                  
Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65                  70                  75                  80  
Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Asn Trp Glu Gly Asp Asn Trp Gly Gln Gly Thr Thr Leu
            100                 105                 110         
Thr Val Ser Ser
        115     


<210> 20
<211> 112
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody light chain V region of MAB2

<400> 20
Asp Val Val Leu Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly
 1               5                  10                  15      
Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Phe Asp Ser
            20                  25                  30          
Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser
        35                  40                  45              
Pro Lys Arg Leu Val Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro
    50                  55                  60                  
Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Tyr Phe Thr Leu Lys Ile
65                  70                  75                  80  
Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys Trp Gln Gly
                85                  90                  95      
Thr His Phe Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
            100                 105                 110         


<210> 21
<211> 348
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain V region of MAB2

<400> 21
gaggtccagc tgcaacaatc tggacctgag ctggtgaagc ctgggacttc agtgaagata 60
tcctgtaagg cttctggata cacgttcact gactcctaca tgaactggat gaaggagagc 120
catggaaaga gccttgagtg gattggagat attaatccta acaatggtgg tactagttac 180
aaccggaagt tcaagggcaa ggccacattg actgtagaca agtcctccag cacagcctac 240
atggagctcc gcagcctgac atctgaggac tctgcagtct attactgtgc aagagagaac 300
tgggaagggg acaactgggg ccaaggcacc actctcacag tctcctca              348

<210> 22
<211> 336
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody light chain V region of MAB2

<400> 22
gatgttgtgc tgacccagac tccactcact ttgtcggtta ccattggaca accagcctcc 60
atctcctgca agtcaagtca gagcctcttc gatagtgatg gaaagacata tttgaattgg 120
ttgttacaga ggccaggcca gtctccaaag cgcctagtct atctggtgtc taaactggac 180
tctggagtcc ctgacaggtt cactggcagt ggatcaggga catatttcac actgaaaatc 240
agcagagtgg aggctgagga tttgggaatt tattattgct ggcaaggtac acattttcca 300
ttcacgttcg gctcggggac aaagttggaa attaaa                           336

<210> 23
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRH2 of MAB3 and MAB8
      according to Chothia, heavy chain V region CDR2

<400> 23
Asn Pro Asp Asn Ala Ile
 1               5      


<210> 24
<211> 12
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRL1 of MAB3, MAB4, MAB5,
      MAB6 and MAB7  according to Chothia, light chain V
      region CDR1

<400> 24
Ser Gln Ser Leu Arg Asp Ser Asp Gly Lys Thr Tyr
 1               5                  10          


<210> 25
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRH2 of MAB3 according to
      Kabat, heavy chain V region CDR2

<400> 25
Asp Ile Asn Pro Asp Asn Ala Ile Thr Ser Tyr Asn Gln Lys Phe Arg
 1               5                  10                  15      
Gly
    

<210> 26
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRL1 of MAB3, MAB4, MAB5,
      MAB6 and MAB7 according to Kabat, light chain V
      region CDR1

<400> 26
Arg Ser Ser Gln Ser Leu Arg Asp Ser Asp Gly Lys Thr Tyr Leu Asn
 1               5                  10                  15      


<210> 27
<211> 116
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain V region of MAB3

<400> 27
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser
            20                  25                  30          
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile
        35                  40                  45              
Gly Asp Ile Asn Pro Asp Asn Ala Ile Thr Ser Tyr Asn Gln Lys Phe
    50                  55                  60                  
Arg Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65                  70                  75                  80  
Met Glu Leu Arg Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Asp Tyr Asn Ser Asp Asp Trp Gly Gln Gly Thr Leu Val
            100                 105                 110         
Thr Val Ser Ser
        115     


<210> 28
<211> 112
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody light chain V region of MAB3

<400> 28
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
 1               5                  10                  15      
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Arg Asp Ser
            20                  25                  30          
Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser
        35                  40                  45              
Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro
    50                  55                  60                  
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65                  70                  75                  80  
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Trp Gln Gly
                85                  90                  95      
Thr His Phe Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
            100                 105                 110         


<210> 29
<211> 446
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain of MAB3

<400> 29
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser
            20                  25                  30          
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile
        35                  40                  45              
Gly Asp Ile Asn Pro Asp Asn Ala Ile Thr Ser Tyr Asn Gln Lys Phe
    50                  55                  60                  
Arg Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65                  70                  75                  80  
Met Glu Leu Arg Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Asp Tyr Asn Ser Asp Asp Trp Gly Gln Gly Thr Leu Val
            100                 105                 110         
Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
        115                 120                 125             
Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu
    130                 135                 140                 
Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
145                 150                 155                 160 
Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
                165                 170                 175     
Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu
            180                 185                 190         
Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
        195                 200                 205             
Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr
    210                 215                 220                 
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
225                 230                 235                 240 
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
                245                 250                 255     
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
            260                 265                 270         
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
        275                 280                 285             
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
    290                 295                 300                 
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
305                 310                 315                 320 
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
                325                 330                 335     
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
            340                 345                 350         
Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
        355                 360                 365             
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
    370                 375                 380                 
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
385                 390                 395                 400 
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
                405                 410                 415     
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
            420                 425                 430         
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
        435                 440                 445     


<210> 30
<211> 219
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody light chain of MAB3, MAB4,
      MAB5, MAB6 and MAB7

<400> 30
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
 1               5                  10                  15      
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Arg Asp Ser
            20                  25                  30          
Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser
        35                  40                  45              
Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro
    50                  55                  60                  
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65                  70                  75                  80  
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Trp Gln Gly
                85                  90                  95      
Thr His Phe Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
            100                 105                 110         
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
        115                 120                 125             
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
    130                 135                 140                 
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145                 150                 155                 160 
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
                165                 170                 175     
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
            180                 185                 190         
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
        195                 200                 205             
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
    210                 215                 


<210> 31
<211> 348
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain V region of MAB3

<400> 31
caggtgcagc tggttcagag tggcgcagaa gtgaaaaaac cgggtgcgag cgtgaaagtt 60
tcttgcaaag ccagtggcta tacctttacg gatagctaca tgaattgggt tcgtcaggca 120
ccgggtcagc gtctggaatg gatcggcgat attaacccgg ataatgcgat cacgtcttat 180
aaccagaaat tccggggtcg tgtgaccatg acgcgcgata cgtctacgtc caccgtgtac 240
atggaactga ggtctctgcg tagcgaagat accgcggtgt attactgtgc ccgcgaagat 300
tataactctg atgattgggg ccagggtacc cttgtgaccg tgagctcc              348

<210> 32
<211> 336
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody light chain V region of MAB3,
      MAB4, MAB5, MAB6 and MAB7

<400> 32
gatgtggtta tgacgcagtc tccgctgagt ctgccggtga ccctgggtca gccggcgagt 60
attagctgcc gtagctctca gagcctgagg gattctgatg gtaaaacgta cctgaattgg 120
ctcctgcagc gtccgggtca gagcccgaag cgcctgattt atttagttag taagttagat 180
agcggcgttc cggatcgttt ctctggcagt ggtagcggca ccgattttac gctgaaaatc 240
tctcgcgtgg aagccgaaga tgtgggtgtt tattactgtt ggcagggcac ccattttccg 300
ttcacgtttg gtagcggcac caagcttgaa attaaa                           336

<210> 33
<211> 1338
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain of MAB3

<400> 33
caggtgcagc tggttcagag tggcgcagaa gtgaaaaaac cgggtgcgag cgtgaaagtt 60
tcttgcaaag ccagtggcta tacctttacg gatagctaca tgaattgggt tcgtcaggca 120
ccgggtcagc gtctggaatg gatcggcgat attaacccgg ataatgcgat cacgtcttat 180
aaccagaaat tccggggtcg tgtgaccatg acgcgcgata cgtctacgtc caccgtgtac 240
atggaactga ggtctctgcg tagcgaagat accgcggtgt attactgtgc ccgcgaagat 300
tataactctg atgattgggg ccagggtacc cttgtgaccg tgagctccgc tagcaccaag 360
ggccccagcg tgttccccct ggcccccagc agcaagagca ccagcggcgg cacagccgcc 420
ctgggctgcc tggtgaagga ctacttcccc gagcccgtga ccgtgtcctg gaacagcgga 480
gccctgacct ccggcgtgca caccttcccc gccgtgctgc agagcagcgg cctgtacagc 540
ctgtccagcg tggtgacagt gcccagcagc agcctgggca cccagaccta catctgcaac 600
gtgaaccaca agcccagcaa caccaaggtg gacaagagag tggagcccaa gagctgcgac 660
aagacccaca cctgcccccc ctgcccagcc ccagagctgc tgggcggacc ctccgtgttc 720
ctgttccccc ccaagcccaa ggacaccctg atgatcagca ggacccccga ggtgacctgc 780
gtggtggtgg acgtgagcca cgaggaccca gaggtgaagt tcaactggta cgtggacggc 840
gtggaggtgc acaacgccaa gaccaagccc agagaggagc agtacaacag cacctacagg 900
gtggtgtccg tgctgaccgt gctgcaccag gactggctga acggcaagga atacaagtgc 960
aaggtctcca acaaggccct gccagccccc atcgaaaaga ccatcagcaa ggccaagggc 1020
cagccacggg agccccaggt gtacaccctg cccccctccc gggaggagat gaccaagaac 1080
caggtgtccc tgacctgtct ggtgaagggc ttctacccca gcgacatcgc cgtggagtgg 1140
gagagcaacg gccagcccga gaacaactac aagaccaccc ccccagtgct ggacagcgac 1200
ggcagcttct tcctgtacag caagctgacc gtggacaagt ccaggtggca gcagggcaac 1260
gtgttcagct gcagcgtgat gcacgaggcc ctgcacaacc actacaccca gaagagcctg 1320
agcctgtccc ccggcaag                                               1338

<210> 34
<211> 657
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody light chain of MAB3, MAB4,
      MAB5, MAB6 and MAB7

<400> 34
gatgtggtta tgacgcagtc tccgctgagt ctgccggtga ccctgggtca gccggcgagt 60
attagctgcc gtagctctca gagcctgagg gattctgatg gtaaaacgta cctgaattgg 120
ctcctgcagc gtccgggtca gagcccgaag cgcctgattt atttagttag taagttagat 180
agcggcgttc cggatcgttt ctctggcagt ggtagcggca ccgattttac gctgaaaatc 240
tctcgcgtgg aagccgaaga tgtgggtgtt tattactgtt ggcagggcac ccattttccg 300
ttcacgtttg gtagcggcac caagcttgaa attaaacgta cggtggccgc tcccagcgtg 360
ttcatcttcc cccccagcga cgagcagctg aagagcggca ccgccagcgt ggtgtgcctg 420
ctgaacaact tctacccccg ggaggccaag gtgcagtgga aggtggacaa cgccctgcag 480
agcggcaaca gccaggagag cgtcaccgag caggacagca aggactccac ctacagcctg 540
agcagcaccc tgaccctgag caaggccgac tacgagaagc ataaggtgta cgcctgcgag 600
gtgacccacc agggcctgtc cagccccgtg accaagagct tcaacagggg cgagtgc    657

<210> 35
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRH2 of MAB4 and MAB8
      according to Kabat, heavy chain V region CDR2

<400> 35
Asp Ile Asn Pro Asp Asn Ala Ile Thr Ser Tyr Asn Arg Lys Phe Arg
 1               5                  10                  15      
Gly
    

<210> 36
<211> 116
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain V region of MAB4

<400> 36
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser
            20                  25                  30          
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile
        35                  40                  45              
Gly Asp Ile Asn Pro Asp Asn Ala Ile Thr Ser Tyr Asn Arg Lys Phe
    50                  55                  60                  
Arg Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65                  70                  75                  80  
Met Glu Leu Arg Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Asp Tyr Asn Ser Asp Asp Trp Gly Gln Gly Thr Leu Val
            100                 105                 110         
Thr Val Ser Ser
        115     


<210> 37
<211> 446
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain of MAB4

<400> 37
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser
            20                  25                  30          
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile
        35                  40                  45              
Gly Asp Ile Asn Pro Asp Asn Ala Ile Thr Ser Tyr Asn Arg Lys Phe
    50                  55                  60                  
Arg Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65                  70                  75                  80  
Met Glu Leu Arg Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Asp Tyr Asn Ser Asp Asp Trp Gly Gln Gly Thr Leu Val
            100                 105                 110         
Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
        115                 120                 125             
Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu
    130                 135                 140                 
Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
145                 150                 155                 160 
Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
                165                 170                 175     
Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu
            180                 185                 190         
Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
        195                 200                 205             
Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr
    210                 215                 220                 
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
225                 230                 235                 240 
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
                245                 250                 255     
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
            260                 265                 270         
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
        275                 280                 285             
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
    290                 295                 300                 
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
305                 310                 315                 320 
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
                325                 330                 335     
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
            340                 345                 350         
Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
        355                 360                 365             
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
    370                 375                 380                 
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
385                 390                 395                 400 
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
                405                 410                 415     
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
            420                 425                 430         
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
        435                 440                 445     


<210> 38
<211> 348
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain V region of MAB4

<400> 38
caggtgcagc tggttcagag tggcgcagaa gtgaaaaaac cgggtgcgag cgtgaaagtt 60
tcttgcaaag ccagtggcta tacctttacg gatagctaca tgaattgggt tcgtcaggca 120
ccgggtcagc gtctggaatg gatcggcgat attaacccgg ataatgcgat cacgtcttat 180
aaccgtaaat tccggggtcg tgtgaccatg acgcgcgata cgtctacgtc caccgtgtac 240
atggaactga ggtctctgcg tagcgaagat accgcggtgt attactgtgc ccgcgaagat 300
tataactctg atgattgggg ccagggtacc cttgtgaccg tgagctcc              348

<210> 39
<211> 1338
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain of MAB4

<400> 39
caggtgcagc tggttcagag tggcgcagaa gtgaaaaaac cgggtgcgag cgtgaaagtt 60
tcttgcaaag ccagtggcta tacctttacg gatagctaca tgaattgggt tcgtcaggca 120
ccgggtcagc gtctggaatg gatcggcgat attaacccgg ataatgcgat cacgtcttat 180
aaccgtaaat tccggggtcg tgtgaccatg acgcgcgata cgtctacgtc caccgtgtac 240
atggaactga ggtctctgcg tagcgaagat accgcggtgt attactgtgc ccgcgaagat 300
tataactctg atgattgggg ccagggtacc cttgtgaccg tgagctccgc tagcaccaag 360
ggccccagcg tgttccccct ggcccccagc agcaagagca ccagcggcgg cacagccgcc 420
ctgggctgcc tggtgaagga ctacttcccc gagcccgtga ccgtgtcctg gaacagcgga 480
gccctgacct ccggcgtgca caccttcccc gccgtgctgc agagcagcgg cctgtacagc 540
ctgtccagcg tggtgacagt gcccagcagc agcctgggca cccagaccta catctgcaac 600
gtgaaccaca agcccagcaa caccaaggtg gacaagagag tggagcccaa gagctgcgac 660
aagacccaca cctgcccccc ctgcccagcc ccagagctgc tgggcggacc ctccgtgttc 720
ctgttccccc ccaagcccaa ggacaccctg atgatcagca ggacccccga ggtgacctgc 780
gtggtggtgg acgtgagcca cgaggaccca gaggtgaagt tcaactggta cgtggacggc 840
gtggaggtgc acaacgccaa gaccaagccc agagaggagc agtacaacag cacctacagg 900
gtggtgtccg tgctgaccgt gctgcaccag gactggctga acggcaagga atacaagtgc 960
aaggtctcca acaaggccct gccagccccc atcgaaaaga ccatcagcaa ggccaagggc 1020
cagccacggg agccccaggt gtacaccctg cccccctccc gggaggagat gaccaagaac 1080
caggtgtccc tgacctgtct ggtgaagggc ttctacccca gcgacatcgc cgtggagtgg 1140
gagagcaacg gccagcccga gaacaactac aagaccaccc ccccagtgct ggacagcgac 1200
ggcagcttct tcctgtacag caagctgacc gtggacaagt ccaggtggca gcagggcaac 1260
gtgttcagct gcagcgtgat gcacgaggcc ctgcacaacc actacaccca gaagagcctg 1320
agcctgtccc ccggcaag                                               1338

<210> 40
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRH2 of MAB5 according to
      Chothia, heavy chain V region CDR2

<400> 40
Asn Pro Asp Asn Ala Arg
 1               5      


<210> 41
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRH2 of MAB5 according to
      Kabat, heavy chain V region CDR2

<400> 41
Asp Ile Asn Pro Asp Asn Ala Arg Thr Ser Tyr Asn Arg Lys Phe Arg
 1               5                  10                  15      
Gly
    

<210> 42
<211> 116
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain V region of MAB5

<400> 42
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser
            20                  25                  30          
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile
        35                  40                  45              
Gly Asp Ile Asn Pro Asp Asn Ala Arg Thr Ser Tyr Asn Arg Lys Phe
    50                  55                  60                  
Arg Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65                  70                  75                  80  
Met Glu Leu Arg Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Asp Tyr Asn Ser Asp Asp Trp Gly Gln Gly Thr Leu Val
            100                 105                 110         
Thr Val Ser Ser
        115     


<210> 43
<211> 446
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain of MAB5

<400> 43
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser
            20                  25                  30          
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile
        35                  40                  45              
Gly Asp Ile Asn Pro Asp Asn Ala Arg Thr Ser Tyr Asn Arg Lys Phe
    50                  55                  60                  
Arg Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65                  70                  75                  80  
Met Glu Leu Arg Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Asp Tyr Asn Ser Asp Asp Trp Gly Gln Gly Thr Leu Val
            100                 105                 110         
Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
        115                 120                 125             
Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu
    130                 135                 140                 
Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
145                 150                 155                 160 
Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
                165                 170                 175     
Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu
            180                 185                 190         
Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
        195                 200                 205             
Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr
    210                 215                 220                 
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
225                 230                 235                 240 
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
                245                 250                 255     
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
            260                 265                 270         
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
        275                 280                 285             
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
    290                 295                 300                 
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
305                 310                 315                 320 
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
                325                 330                 335     
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
            340                 345                 350         
Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
        355                 360                 365             
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
    370                 375                 380                 
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
385                 390                 395                 400 
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
                405                 410                 415     
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
            420                 425                 430         
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
        435                 440                 445     


<210> 44
<211> 348
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain V region of MAB5

<400> 44
caggtgcagc tggttcagag tggcgcagaa gtgaaaaaac cgggtgcgag cgtgaaagtt 60
tcttgcaaag ccagtggcta tacctttacg gatagctaca tgaattgggt tcgtcaggca 120
ccgggtcagc gtctggaatg gatcggcgat attaacccgg ataatgcgag gacgtcttat 180
aaccgtaaat tccggggtcg tgtgaccatg acgcgcgata cgtctacgtc caccgtgtac 240
atggaactga ggtctctgcg tagcgaagat accgcggtgt attactgtgc ccgcgaagat 300
tataactctg atgattgggg ccagggtacc cttgtgaccg tgagctcc              348

<210> 45
<211> 1338
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain of MAB5

<400> 45
caggtgcagc tggttcagag tggcgcagaa gtgaaaaaac cgggtgcgag cgtgaaagtt 60
tcttgcaaag ccagtggcta tacctttacg gatagctaca tgaattgggt tcgtcaggca 120
ccgggtcagc gtctggaatg gatcggcgat attaacccgg ataatgcgag gacgtcttat 180
aaccgtaaat tccggggtcg tgtgaccatg acgcgcgata cgtctacgtc caccgtgtac 240
atggaactga ggtctctgcg tagcgaagat accgcggtgt attactgtgc ccgcgaagat 300
tataactctg atgattgggg ccagggtacc cttgtgaccg tgagctccgc tagcaccaag 360
ggccccagcg tgttccccct ggcccccagc agcaagagca ccagcggcgg cacagccgcc 420
ctgggctgcc tggtgaagga ctacttcccc gagcccgtga ccgtgtcctg gaacagcgga 480
gccctgacct ccggcgtgca caccttcccc gccgtgctgc agagcagcgg cctgtacagc 540
ctgtccagcg tggtgacagt gcccagcagc agcctgggca cccagaccta catctgcaac 600
gtgaaccaca agcccagcaa caccaaggtg gacaagagag tggagcccaa gagctgcgac 660
aagacccaca cctgcccccc ctgcccagcc ccagagctgc tgggcggacc ctccgtgttc 720
ctgttccccc ccaagcccaa ggacaccctg atgatcagca ggacccccga ggtgacctgc 780
gtggtggtgg acgtgagcca cgaggaccca gaggtgaagt tcaactggta cgtggacggc 840
gtggaggtgc acaacgccaa gaccaagccc agagaggagc agtacaacag cacctacagg 900
gtggtgtccg tgctgaccgt gctgcaccag gactggctga acggcaagga atacaagtgc 960
aaggtctcca acaaggccct gccagccccc atcgaaaaga ccatcagcaa ggccaagggc 1020
cagccacggg agccccaggt gtacaccctg cccccctccc gggaggagat gaccaagaac 1080
caggtgtccc tgacctgtct ggtgaagggc ttctacccca gcgacatcgc cgtggagtgg 1140
gagagcaacg gccagcccga gaacaactac aagaccaccc ccccagtgct ggacagcgac 1200
ggcagcttct tcctgtacag caagctgacc gtggacaagt ccaggtggca gcagggcaac 1260
gtgttcagct gcagcgtgat gcacgaggcc ctgcacaacc actacaccca gaagagcctg 1320
agcctgtccc ccggcaag                                               1338

<210> 46
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRH2 of MAB6 according to
      Chothia, heavy chain V region CDR2

<400> 46
Asn Pro Lys Asn Ala Arg
 1               5      


<210> 47
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRH2 of MAB6 according to
      Kabat, heavy chain V region CDR2

<400> 47
Asp Ile Asn Pro Lys Asn Ala Arg Thr Ser Tyr Asn Arg Lys Phe Arg
 1               5                  10                  15      
Gly
    

<210> 48
<211> 116
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain V region of MAB6

<400> 48
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser
            20                  25                  30          
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile
        35                  40                  45              
Gly Asp Ile Asn Pro Lys Asn Ala Arg Thr Ser Tyr Asn Arg Lys Phe
    50                  55                  60                  
Arg Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65                  70                  75                  80  
Met Glu Leu Arg Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Asp Tyr Asn Ser Asp Asp Trp Gly Gln Gly Thr Leu Val
            100                 105                 110         
Thr Val Ser Ser
        115     


<210> 49
<211> 446
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain V region of MAB6

<400> 49
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser
            20                  25                  30          
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile
        35                  40                  45              
Gly Asp Ile Asn Pro Lys Asn Ala Arg Thr Ser Tyr Asn Arg Lys Phe
    50                  55                  60                  
Arg Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65                  70                  75                  80  
Met Glu Leu Arg Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Asp Tyr Asn Ser Asp Asp Trp Gly Gln Gly Thr Leu Val
            100                 105                 110         
Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
        115                 120                 125             
Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu
    130                 135                 140                 
Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
145                 150                 155                 160 
Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
                165                 170                 175     
Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu
            180                 185                 190         
Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
        195                 200                 205             
Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr
    210                 215                 220                 
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
225                 230                 235                 240 
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
                245                 250                 255     
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
            260                 265                 270         
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
        275                 280                 285             
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
    290                 295                 300                 
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
305                 310                 315                 320 
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
                325                 330                 335     
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
            340                 345                 350         
Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
        355                 360                 365             
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
    370                 375                 380                 
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
385                 390                 395                 400 
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
                405                 410                 415     
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
            420                 425                 430         
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
        435                 440                 445     


<210> 50
<211> 348
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain V region of MAB6

<400> 50
caggtgcagc tggttcagag tggcgcagaa gtgaaaaaac cgggtgcgag cgtgaaagtt 60
tcttgcaaag ccagtggcta tacctttacg gatagctaca tgaattgggt tcgtcaggca 120
ccgggtcagc gtctggaatg gatcggcgat attaacccga agaatgcgag gacgtcttat 180
aaccgtaaat tccggggtcg tgtgaccatg acgcgcgata cgtctacgtc caccgtgtac 240
atggaactga ggtctctgcg tagcgaagat accgcggtgt attactgtgc ccgcgaagat 300
tataactctg atgattgggg ccagggtacc cttgtgaccg tgagctcc              348

<210> 51
<211> 1338
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain of MAB6

<400> 51
caggtgcagc tggttcagag tggcgcagaa gtgaaaaaac cgggtgcgag cgtgaaagtt 60
tcttgcaaag ccagtggcta tacctttacg gatagctaca tgaattgggt tcgtcaggca 120
ccgggtcagc gtctggaatg gatcggcgat attaacccga agaatgcgag gacgtcttat 180
aaccgtaaat tccggggtcg tgtgaccatg acgcgcgata cgtctacgtc caccgtgtac 240
atggaactga ggtctctgcg tagcgaagat accgcggtgt attactgtgc ccgcgaagat 300
tataactctg atgattgggg ccagggtacc cttgtgaccg tgagctccgc tagcaccaag 360
ggccccagcg tgttccccct ggcccccagc agcaagagca ccagcggcgg cacagccgcc 420
ctgggctgcc tggtgaagga ctacttcccc gagcccgtga ccgtgtcctg gaacagcgga 480
gccctgacct ccggcgtgca caccttcccc gccgtgctgc agagcagcgg cctgtacagc 540
ctgtccagcg tggtgacagt gcccagcagc agcctgggca cccagaccta catctgcaac 600
gtgaaccaca agcccagcaa caccaaggtg gacaagagag tggagcccaa gagctgcgac 660
aagacccaca cctgcccccc ctgcccagcc ccagagctgc tgggcggacc ctccgtgttc 720
ctgttccccc ccaagcccaa ggacaccctg atgatcagca ggacccccga ggtgacctgc 780
gtggtggtgg acgtgagcca cgaggaccca gaggtgaagt tcaactggta cgtggacggc 840
gtggaggtgc acaacgccaa gaccaagccc agagaggagc agtacaacag cacctacagg 900
gtggtgtccg tgctgaccgt gctgcaccag gactggctga acggcaagga atacaagtgc 960
aaggtctcca acaaggccct gccagccccc atcgaaaaga ccatcagcaa ggccaagggc 1020
cagccacggg agccccaggt gtacaccctg cccccctccc gggaggagat gaccaagaac 1080
caggtgtccc tgacctgtct ggtgaagggc ttctacccca gcgacatcgc cgtggagtgg 1140
gagagcaacg gccagcccga gaacaactac aagaccaccc ccccagtgct ggacagcgac 1200
ggcagcttct tcctgtacag caagctgacc gtggacaagt ccaggtggca gcagggcaac 1260
gtgttcagct gcagcgtgat gcacgaggcc ctgcacaacc actacaccca gaagagcctg 1320
agcctgtccc ccggcaag                                               1338

<210> 52
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRH2 of MAB7 according to
      Chothia, heavy chain V region CDR2

<400> 52
Asn Pro Lys Asn Ala Tyr
 1               5      


<210> 53
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRH2 of MAB7 according to
      Kabat, heavy chain V region CDR2

<400> 53
Asp Ile Asn Pro Lys Asn Ala Tyr Thr Ser Tyr Asn Arg Lys Phe Arg
 1               5                  10                  15      
Gly
    

<210> 54
<211> 116
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain V region of MAB7

<400> 54
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser
            20                  25                  30          
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile
        35                  40                  45              
Gly Asp Ile Asn Pro Lys Asn Ala Tyr Thr Ser Tyr Asn Arg Lys Phe
    50                  55                  60                  
Arg Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65                  70                  75                  80  
Met Glu Leu Arg Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Asp Tyr Asn Ser Asp Asp Trp Gly Gln Gly Thr Leu Val
            100                 105                 110         
Thr Val Ser Ser
        115     


<210> 55
<211> 446
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain of MAB7

<400> 55
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser
            20                  25                  30          
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile
        35                  40                  45              
Gly Asp Ile Asn Pro Lys Asn Ala Tyr Thr Ser Tyr Asn Arg Lys Phe
    50                  55                  60                  
Arg Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65                  70                  75                  80  
Met Glu Leu Arg Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Asp Tyr Asn Ser Asp Asp Trp Gly Gln Gly Thr Leu Val
            100                 105                 110         
Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
        115                 120                 125             
Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu
    130                 135                 140                 
Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
145                 150                 155                 160 
Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
                165                 170                 175     
Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu
            180                 185                 190         
Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
        195                 200                 205             
Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr
    210                 215                 220                 
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
225                 230                 235                 240 
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
                245                 250                 255     
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
            260                 265                 270         
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
        275                 280                 285             
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
    290                 295                 300                 
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
305                 310                 315                 320 
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
                325                 330                 335     
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
            340                 345                 350         
Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
        355                 360                 365             
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
    370                 375                 380                 
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
385                 390                 395                 400 
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
                405                 410                 415     
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
            420                 425                 430         
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
        435                 440                 445     


<210> 56
<211> 348
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain V region of MAB7

<400> 56
caggtgcagc tggttcagag tggcgcagaa gtgaaaaaac cgggtgcgag cgtgaaagtt 60
tcttgcaaag ccagtggcta tacctttacg gatagctaca tgaattgggt tcgtcaggca 120
ccgggtcagc gtctggaatg gatcggcgat attaacccga agaatgcgta tacgtcttat 180
aaccgtaaat tccggggtcg tgtgaccatg acgcgcgata cgtctacgtc caccgtgtac 240
atggaactga ggtctctgcg tagcgaagat accgcggtgt attactgtgc ccgcgaagat 300
tataactctg atgattgggg ccagggtacc cttgtgaccg tgagctcc              348

<210> 57
<211> 1338
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain of MAB7

<400> 57
caggtgcagc tggttcagag tggcgcagaa gtgaaaaaac cgggtgcgag cgtgaaagtt 60
tcttgcaaag ccagtggcta tacctttacg gatagctaca tgaattgggt tcgtcaggca 120
ccgggtcagc gtctggaatg gatcggcgat attaacccga agaatgcgta tacgtcttat 180
aaccgtaaat tccggggtcg tgtgaccatg acgcgcgata cgtctacgtc caccgtgtac 240
atggaactga ggtctctgcg tagcgaagat accgcggtgt attactgtgc ccgcgaagat 300
tataactctg atgattgggg ccagggtacc cttgtgaccg tgagctccgc tagcaccaag 360
ggccccagcg tgttccccct ggcccccagc agcaagagca ccagcggcgg cacagccgcc 420
ctgggctgcc tggtgaagga ctacttcccc gagcccgtga ccgtgtcctg gaacagcgga 480
gccctgacct ccggcgtgca caccttcccc gccgtgctgc agagcagcgg cctgtacagc 540
ctgtccagcg tggtgacagt gcccagcagc agcctgggca cccagaccta catctgcaac 600
gtgaaccaca agcccagcaa caccaaggtg gacaagagag tggagcccaa gagctgcgac 660
aagacccaca cctgcccccc ctgcccagcc ccagagctgc tgggcggacc ctccgtgttc 720
ctgttccccc ccaagcccaa ggacaccctg atgatcagca ggacccccga ggtgacctgc 780
gtggtggtgg acgtgagcca cgaggaccca gaggtgaagt tcaactggta cgtggacggc 840
gtggaggtgc acaacgccaa gaccaagccc agagaggagc agtacaacag cacctacagg 900
gtggtgtccg tgctgaccgt gctgcaccag gactggctga acggcaagga atacaagtgc 960
aaggtctcca acaaggccct gccagccccc atcgaaaaga ccatcagcaa ggccaagggc 1020
cagccacggg agccccaggt gtacaccctg cccccctccc gggaggagat gaccaagaac 1080
caggtgtccc tgacctgtct ggtgaagggc ttctacccca gcgacatcgc cgtggagtgg 1140
gagagcaacg gccagcccga gaacaactac aagaccaccc ccccagtgct ggacagcgac 1200
ggcagcttct tcctgtacag caagctgacc gtggacaagt ccaggtggca gcagggcaac 1260
gtgttcagct gcagcgtgat gcacgaggcc ctgcacaacc actacaccca gaagagcctg 1320
agcctgtccc ccggcaag                                               1338

<210> 58
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRH3 of MAB8 according to
      Chothia, heavy chain V region CDR3

<400> 58
Glu Asp Tyr Asn Ala Asp Asp
 1               5          


<210> 59
<211> 12
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRL1 of MAB8 according to
      Chothia, light chain V region CDR1

<400> 59
Ser Gln Ser Leu Arg Asp Ser Ser Gly Lys Thr Tyr
 1               5                  10          


<210> 60
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody CDRL1 of MAB8 according to
      Kabat, lightchain V region CDR1

<400> 60
Arg Ser Ser Gln Ser Leu Arg Asp Ser Ser Gly Lys Thr Tyr Leu Asn
 1               5                  10                  15      


<210> 61
<211> 116
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain V region of MAB8

<400> 61
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser
            20                  25                  30          
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile
        35                  40                  45              
Gly Asp Ile Asn Pro Asp Asn Ala Ile Thr Ser Tyr Asn Arg Lys Phe
    50                  55                  60                  
Arg Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65                  70                  75                  80  
Met Glu Leu Arg Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Asp Tyr Asn Ala Asp Asp Trp Gly Gln Gly Thr Leu Val
            100                 105                 110         
Thr Val Ser Ser
        115     


<210> 62
<211> 112
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody light chain V region MAB8

<400> 62
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
 1               5                  10                  15      
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Arg Asp Ser
            20                  25                  30          
Ser Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser
        35                  40                  45              
Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro
    50                  55                  60                  
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65                  70                  75                  80  
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Trp Gln Gly
                85                  90                  95      
Thr His Phe Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
            100                 105                 110         


<210> 63
<211> 446
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain of MAB8

<400> 63
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser
            20                  25                  30          
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile
        35                  40                  45              
Gly Asp Ile Asn Pro Asp Asn Ala Ile Thr Ser Tyr Asn Arg Lys Phe
    50                  55                  60                  
Arg Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65                  70                  75                  80  
Met Glu Leu Arg Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg Glu Asp Tyr Asn Ala Asp Asp Trp Gly Gln Gly Thr Leu Val
            100                 105                 110         
Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
        115                 120                 125             
Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu
    130                 135                 140                 
Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
145                 150                 155                 160 
Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
                165                 170                 175     
Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu
            180                 185                 190         
Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
        195                 200                 205             
Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr
    210                 215                 220                 
Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
225                 230                 235                 240 
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro
                245                 250                 255     
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
            260                 265                 270         
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
        275                 280                 285             
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
    290                 295                 300                 
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
305                 310                 315                 320 
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
                325                 330                 335     
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
            340                 345                 350         
Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
        355                 360                 365             
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
    370                 375                 380                 
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
385                 390                 395                 400 
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
                405                 410                 415     
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
            420                 425                 430         
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
        435                 440                 445     


<210> 64
<211> 219
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody light chain of MAB8

<400> 64
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
 1               5                  10                  15      
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Arg Asp Ser
            20                  25                  30          
Ser Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser
        35                  40                  45              
Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro
    50                  55                  60                  
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65                  70                  75                  80  
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Trp Gln Gly
                85                  90                  95      
Thr His Phe Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
            100                 105                 110         
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
        115                 120                 125             
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
    130                 135                 140                 
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145                 150                 155                 160 
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
                165                 170                 175     
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
            180                 185                 190         
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
        195                 200                 205             
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
    210                 215                 


<210> 65
<211> 348
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain V region of MAB8

<400> 65
caggtgcagc tggttcagag tggcgcagaa gtgaaaaaac cgggtgcgag cgtgaaagtt 60
tcttgcaaag ccagtggcta tacctttacg gatagctaca tgaattgggt tcgtcaggca 120
ccgggtcagc gtctggaatg gatcggcgat attaacccgg ataatgcgat cacgtcttat 180
aaccgtaaat tccggggtcg tgtgaccatg acgcgcgata cgtctacgtc caccgtgtac 240
atggaactga ggtctctgcg tagcgaagat accgcggtgt attactgtgc ccgcgaagat 300
tataacgccg atgattgggg ccagggtacc cttgtgaccg tgagctcc              348

<210> 66
<211> 336
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody light chain V region of MAB8

<400> 66
gatgtggtta tgacgcagtc tccgctgagt ctgccggtga ccctgggtca gccggcgagt 60
attagctgcc gtagctctca gagcctgagg gattcttccg gtaaaacgta cctgaattgg 120
ctcctgcagc gtccgggtca gagcccgaag cgcctgattt atttagttag taagttagat 180
agcggcgttc cggatcgttt ctctggcagt ggtagcggca ccgattttac gctgaaaatc 240
tctcgcgtgg aagccgaaga tgtgggtgtt tattactgtt ggcagggcac ccattttccg 300
ttcacgtttg gtagcggcac caagcttgaa attaaa                           336

<210> 67
<211> 1338
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain of MAB8

<400> 67
caggtgcagc tggttcagag tggcgcagaa gtgaaaaaac cgggtgcgag cgtgaaagtt 60
tcttgcaaag ccagtggcta tacctttacg gatagctaca tgaattgggt tcgtcaggca 120
ccgggtcagc gtctggaatg gatcggcgat attaacccgg ataatgcgat cacgtcttat 180
aaccgtaaat tccggggtcg tgtgaccatg acgcgcgata cgtctacgtc caccgtgtac 240
atggaactga ggtctctgcg tagcgaagat accgcggtgt attactgtgc ccgcgaagat 300
tataacgccg atgattgggg ccagggtacc cttgtgaccg tgagctccgc tagcaccaag 360
ggccccagcg tgttccccct ggcccccagc agcaagagca ccagcggcgg cacagccgcc 420
ctgggctgcc tggtgaagga ctacttcccc gagcccgtga ccgtgtcctg gaacagcgga 480
gccctgacct ccggcgtgca caccttcccc gccgtgctgc agagcagcgg cctgtacagc 540
ctgtccagcg tggtgacagt gcccagcagc agcctgggca cccagaccta catctgcaac 600
gtgaaccaca agcccagcaa caccaaggtg gacaagagag tggagcccaa gagctgcgac 660
aagacccaca cctgcccccc ctgcccagcc ccagagctgc tgggcggacc ctccgtgttc 720
ctgttccccc ccaagcccaa ggacaccctg atgatcagca ggacccccga ggtgacctgc 780
gtggtggtgg acgtgagcca cgaggaccca gaggtgaagt tcaactggta cgtggacggc 840
gtggaggtgc acaacgccaa gaccaagccc agagaggagc agtacaacag cacctacagg 900
gtggtgtccg tgctgaccgt gctgcaccag gactggctga acggcaagga atacaagtgc 960
aaggtctcca acaaggccct gccagccccc atcgaaaaga ccatcagcaa ggccaagggc 1020
cagccacggg agccccaggt gtacaccctg cccccctccc gggaggagat gaccaagaac 1080
caggtgtccc tgacctgtct ggtgaagggc ttctacccca gcgacatcgc cgtggagtgg 1140
gagagcaacg gccagcccga gaacaactac aagaccaccc ccccagtgct ggacagcgac 1200
ggcagcttct tcctgtacag caagctgacc gtggacaagt ccaggtggca gcagggcaac 1260
gtgttcagct gcagcgtgat gcacgaggcc ctgcacaacc actacaccca gaagagcctg 1320
agcctgtccc ccggcaag                                               1338

<210> 68
<211> 657
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody light chain of MAB8

<400> 68
gatgtggtta tgacgcagtc tccgctgagt ctgccggtga ccctgggtca gccggcgagt 60
attagctgcc gtagctctca gagcctgagg gattcttccg gtaaaacgta cctgaattgg 120
ctcctgcagc gtccgggtca gagcccgaag cgcctgattt atttagttag taagttagat 180
agcggcgttc cggatcgttt ctctggcagt ggtagcggca ccgattttac gctgaaaatc 240
tctcgcgtgg aagccgaaga tgtgggtgtt tattactgtt ggcagggcac ccattttccg 300
ttcacgtttg gtagcggcac caagcttgaa attaaacgta cggtggccgc tcccagcgtg 360
ttcatcttcc cccccagcga cgagcagctg aagagcggca ccgccagcgt ggtgtgcctg 420
ctgaacaact tctacccccg ggaggccaag gtgcagtgga aggtggacaa cgccctgcag 480
agcggcaaca gccaggagag cgtcaccgag caggacagca aggactccac ctacagcctg 540
agcagcaccc tgaccctgag caaggccgac tacgagaagc ataaggtgta cgcctgcgag 600
gtgacccacc agggcctgtc cagccccgtg accaagagct tcaacagggg cgagtgc    657

<210> 69
<211> 98
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic human engineered MAB3-MAB8 consensus
      heavy chain V-segment (FR1-FR3)

<220> 
<221> VARIANT        
<222> (54)...(54)
<223> Xaa = Asp or Lys

<220> 
<221> VARIANT        
<222> (57)...(57)
<223> Xaa= Ile, Arg or Try

<220> 
<221> VARIANT        
<222> (62)...(62)
<223> Xaa = Arg or Gln

<400> 69
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1               5                  10                  15      
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Ser
            20                  25                  30          
Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile
        35                  40                  45              
Gly Asp Ile Asn Pro Xaa Asn Ala Xaa Thr Ser Tyr Asn Xaa Lys Phe
    50                  55                  60                  
Arg Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65                  70                  75                  80  
Met Glu Leu Arg Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
                85                  90                  95      
Ala Arg
        

<210> 70
<211> 93
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic human engineered MAB3-MAB8 consensus
      light chain V-segment (FR1-FR3)

<220> 
<221> VARIANT        
<222> (33)...(33)
<223> Xaa = Asp or Ser

<400> 70
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
 1               5                  10                  15      
Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Arg Asp Ser
            20                  25                  30          
Xaa Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser
        35                  40                  45              
Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro
    50                  55                  60                  
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65                  70                  75                  80  
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys
                85                  90              


<210> 71
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic human germline JH4 partial sequence,
      anti-human interleukin-2 (IL-2) monoclonal
      antibody heavy chain FR4

<400> 71
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 1               5                  10      


<210> 72
<211> 10
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic human germline J-segment Jk2 sequence,
      anti-human interleukin-2 (IL-2) monoclonal
      antibody light chain FR4

<400> 72
Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 1               5                  10  


<210> 73
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain V region CDR3

<220> 
<221> VARIANT        
<222> (5)...(5)
<223> Xaa = Ser or Ala

<400> 73
Glu Asp Tyr Asn Xaa Asp Asp
 1               5          


<210> 74
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain V region CDR2

<220> 
<221> VARIANT        
<222> (5)...(5)
<223> Xaa = Asp, Asn or Lys

<221> VARIANT        
<222> (7)...(7)
<223> Xaa = Gly or Ala

<220> 
<221> VARIANT        
<222> (8)...(8)
<223> Xaa = Ile, Gly, Arg or Tyr

<220> 
<221> VARIANT        
<222> (13)...(13)
<223> Xaa = Gln or Arg

<220> 
<221> VARIANT        
<222> (16)...(16)
<223> Xaa = Arg or Lys

<400> 74
Asp Ile Asn Pro Xaa Asn Xaa Xaa Thr Ser Tyr Asn Xaa Lys Phe Xaa
 1               5                  10                  15      
Gly
    

<210> 75
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain V region CDR2

<220> 
<221> VARIANT        
<222> (5)...(5)
<223> Xaa = Asp or Lys

<220> 
<221> VARIANT        
<222> (8)...(8)
<223> Xaa = Ile, Arg or Tyr

<220> 
<221> VARIANT        
<222> (13)...(13)
<223> Xaa = Gln or Arg

<400> 75
Asp Ile Asn Pro Xaa Asn Ala Xaa Thr Ser Tyr Asn Xaa Lys Phe Arg
 1               5                  10                  15      
Gly
    

<210> 76
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody light chain V region CDR1

<220> 
<221> VARIANT        
<222> (1)...(1)
<223> Xaa = Arg or Lys

<220> 
<221> VARIANT        
<222> (7)...(7)
<223> Xaa = Phe or Arg

<220> 
<221> VARIANT        
<222> (10)...(10)
<223> Xaa = Asp or Ser

<400> 76
Xaa Ser Ser Gln Ser Leu Xaa Asp Ser Xaa Gly Lys Thr Tyr Leu Asn
 1               5                  10                  15      


<210> 77
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody light chain V region CDR1

<220> 
<221> VARIANT        
<222> (10)...(10)
<223> Xaa = Asp or Ser

<400> 77
Arg Ser Ser Gln Ser Leu Arg Asp Ser Xaa Gly Lys Thr Tyr Leu Asn
 1               5                  10                  15      


<210> 78
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody heavy chain V region CDR2

<221> VARIANT        
<222> (3)...(3)
<223> Xaa = Asp, Asn or Lys

<220> 
<221> VARIANT        
<222> (5)...(5)
<223> Xaa = Gly or Ala

<220> 
<221> VARIANT        
<222> (6)...(6)
<223> Xaa = Gly, Ile, Arg or Tyr

<400> 78
Asn Pro Xaa Asn Xaa Xaa
 1               5      


<210> 79
<211> 12
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-human interleukin-2 (IL-2)
      monoclonal antibody light chain V region CDR1

<220> 
<221> VARIANT        
<222> (5)...(5)
<223> Xaa = Phe or Arg

<220> 
<221> VARIANT        
<222> (8)...(8)
<223> Xaa = Asp or Ser

<400> 79
Ser Gln Ser Leu Xaa Asp Ser Xaa Gly Lys Thr Tyr
 1               5                  10          


<210> 80
<211> 15
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic full-length J-segment from human
      germline JH4

<400> 80
Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 1               5                  10                  15  


<210> 81
<211> 52
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic helix A of human interleukin-2 (IL-2),
      hIL2DM1

<400> 81
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
 1               5                  10                  15      
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
            20                  25                  30          
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
        35                  40                  45              
Lys Ala Thr Glu
    50          


<210> 82
<211> 239
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic mouse Fc fusion protein mFc-hIL-2-DM1

<400> 82
Arg Ser Leu Glu Val Leu Phe Gln Gly Arg Gly Ser Pro Pro Leu Lys
 1               5                  10                  15      
Glu Cys Pro Pro Cys Ala Ala Pro Asp Leu Leu Gly Gly Pro Ser Val
            20                  25                  30          
Phe Ile Phe Pro Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser
        35                  40                  45              
Pro Met Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp
    50                  55                  60                  
Val Gln Ile Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln
65                  70                  75                  80  
Thr Gln Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser
                85                  90                  95      
Ala Leu Pro Ile Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys
            100                 105                 110         
Cys Lys Val Asn Asn Arg Ala Leu Pro Ser Pro Ile Glu Lys Thr Ile
        115                 120                 125             
Ser Lys Pro Arg Gly Pro Val Arg Ala Pro Gln Val Tyr Val Leu Pro
    130                 135                 140                 
Pro Pro Ala Glu Glu Met Thr Lys Lys Glu Phe Ser Leu Thr Cys Met
145                 150                 155                 160 
Ile Thr Gly Phe Leu Pro Ala Glu Ile Ala Val Asp Trp Thr Ser Asn
                165                 170                 175     
Gly Arg Thr Glu Gln Asn Tyr Lys Asn Thr Ala Thr Val Leu Asp Ser
            180                 185                 190         
Asp Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Gln Lys Ser Thr
        195                 200                 205             
Trp Glu Arg Gly Ser Leu Phe Ala Cys Ser Val Val His Glu Gly Leu
    210                 215                 220                 
His Asn His Leu Thr Thr Lys Thr Ile Ser Arg Ser Leu Gly Lys
225                 230                 235                 


<210> 83
<211> 34
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic mouse immunoglobulin constant region
      gene specific primer mIgG2b-pO

<220> 
<221> modified_base  
<222> (1)...(1)
<223> t modified by 5' phosphate (Po)

<400> 83
tttacccgga gaccgggaga tggtcttctt cagg                             34

<210> 84
<211> 32
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic mouse immunoglobulin constant region
      gene specific primer CK-pO

<220> 
<221> modified_base  
<222> (1)...(1)
<223> a modified by 5' phosphate (Po)

<400> 84
acactcattc ctgttgaagc tcttgacaat gg                               32

<210> 85
<211> 27
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic heavy chain variable region
      amplification primer mIgG2b CH3-f

<400> 85
ctgaaaaatt actacctgaa gaagacc                                     27

<210> 86
<211> 21
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic heavy chain variable region
      amplification primer mIgG2b CH1-r

<400> 86
gtgtgcacac tgctggacag g                                           21

<210> 87
<211> 24
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic light chain variable region
      amplification primer CK-f

<400> 87
cactcacaag acatcaactt cacc                                        24

<210> 88
<211> 24
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic light chain variable region
      amplification primer CK-r

<400> 88
gatacagttg gtgcagcatc agcc                                        24

<210> 89
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic C-terminal flexible linker and 6-His tag

<400> 89
Ala Ala Gly Ala Ser His His His His His His
 1               5                  10      


<210> 90
<211> 40
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic MAB1 VH amplification primer MAB1VH F

<400> 90
cctggaaggc gtgcactgcg aagtgaaact ggtggagtct                       40

<210> 91
<211> 40
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic MAB1 VH amplification primer MAB1VH R

<400> 91
gctggggccc ttggtgctag ctgcagagac agtgaccaga                       40

<210> 92
<211> 40
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic MAB1 VK amplification primer MAB1VK F

<400> 92
gcttccggac accaccggtg atgttgtgct gacccagact                       40

<210> 93
<211> 40
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic MAB1 VK amplification primer MAB1VK R

<400> 93
gctgggagcg gccaccgtac gttttatttc caactttgtc                       40

<210> 94
<211> 37
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic MAB3 VH amplification primer MAB3VH F

<400> 94
cctggaaggc gtgcactgcc aggtgcagct ggttcag                          37

<210> 95
<211> 37
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic MAB3 VH amplification primer MAB3 VH R

<400> 95
gggcccttgg tgctagcgga gctcacggtc acaaggg                          37

<210> 96
<211> 37
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic MAB3 VH amplification primer MAB3 VK F

<400> 96
gcttccggac accaccggtg atgtggttat gacgcag                          37

<210> 97
<211> 37
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic MAB3 VK amplification primer MAB3 VK R

<400> 97
gggagcggcc accgtacgtt taatttcaag cttggtg                          37

<210> 98
<211> 52
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic helix A of human interleukin-2 (IL-2),
      hIL2DM1 with mutation of residues to Ala (hIL2 A1 on DM1)

<400> 98
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
 1               5                  10                  15      
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
            20                  25                  30          
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Ala Tyr Tyr Met Pro Lys
        35                  40                  45              
Lys Ala Thr Glu
    50          


<210> 99
<211> 52
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic helix A of human interleukin-2 (IL-2),
      hIL2DM1 with mutation of residues to Ala (hIL2 A2 on DM1)

<400> 99
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
 1               5                  10                  15      
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Phe Ala
            20                  25                  30          
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
        35                  40                  45              
Lys Ala Thr Glu
    50          


<210> 100
<211> 52
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic helix A of human interleukin-2 (IL-2),
      hIL2DM1 with mutation of residues to Ala (hIL2 A3 on DM1)

<400> 100
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
 1               5                  10                  15      
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
            20                  25                  30          
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
        35                  40                  45              
Lys Ala Thr Ala
    50          


<210> 101
<211> 52
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic helix A of human interleukin-2 (IL-2),
      hIL2DM1 with mutation of residues to Ala (hIL2 A4 on DM1)

<400> 101
Ala Pro Thr Ser Ser Ser Thr Ala Ala Thr Gln Leu Gln Leu Glu His
 1               5                  10                  15      
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
            20                  25                  30          
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
        35                  40                  45              
Lys Ala Thr Glu
    50          


<210> 102
<211> 52
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic helix A of human interleukin-2 (IL-2),
      hIL2DM1 with mutation of residues to Ala (hIL2 A5 on DM1)

<400> 102
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
 1               5                  10                  15      
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
            20                  25                  30          
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Ala
        35                  40                  45              
Ala Ala Thr Glu
    50          


<210> 103
<211> 52
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic helix A of human interleukin-2 (IL-2),
      hIL2DM1 with mutation of residues to Ala (hIL2 A6 on DM1)

<400> 103
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Ala His
 1               5                  10                  15      
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
            20                  25                  30          
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
        35                  40                  45              
Lys Ala Thr Glu
    50          


<210> 104
<211> 52
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic helix A of human interleukin-2 (IL-2),
      hIL2DM1 with mutation of residues to Ala (hIL2 A7 on DM1)

<400> 104
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
 1               5                  10                  15      
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
            20                  25                  30          
Asn Pro Ala Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
        35                  40                  45              
Lys Ala Thr Glu
    50          

